Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2016-03-03 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于终止审查非公开发行股票申请文件的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding the termination of the review process for a non-public stock issuance application. It references communications with the China Securities Regulatory Commission (CSRC) about the suspension and eventual termination of the administrative review for the 2015 non-public stock issuance. The document does not contain financial statements or detailed financial data but rather informs stakeholders about the cessation of a capital raising process. This fits the category of a Capital/Financing Update (CAP) as it relates to changes in the company's financing activities and capital structure plans.
2016-03-03 Chinese
国信证券股份有限公司关于公司关联交易的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from Guosen Securities regarding a related-party transaction involving Guangdong Taicheng Pharmaceutical Co., Ltd. It discusses the non-public issuance of shares, the involvement of related parties, pricing mechanisms, board approvals, and the fairness and compliance of the transaction. The content focuses on a capital raising event through a non-public share issuance involving related parties, with detailed procedural and regulatory compliance information. This fits the definition of a Capital/Financing Update (CAP), as it provides updates on company fundraising and capital structure changes. The document length is 3214 characters, which is sufficient to contain substantive information rather than just an announcement. There is no indication that this is a full annual or interim report, audit report, or other categories. Therefore, the classification is CAP with high confidence.
2016-03-03 Chinese
国信证券股份有限公司关于公司非公开发行股票摊薄即期回报及其填补措施的的核查意见
Capital/Financing Update Classification · 95% confidence The document is a verification opinion from Guosen Securities regarding the dilution of immediate returns and remedial measures related to a non-public stock issuance by Guangdong Taicheng Pharmaceutical Co., Ltd. It references regulatory guidelines and includes commitments from company directors and controlling shareholders. The content focuses on the verification and opinion of the sponsor on the dilution impact and remedial measures, rather than presenting financial statements or detailed financial results. The document length is short (1797 characters) and it is essentially a verification opinion, not a full financial report or announcement of voting results. This fits best under the category of Capital/Financing Update (CAP), as it relates to non-public stock issuance and associated measures.
2016-03-03 Chinese
独立董事关于2016年非公开发行股票涉及关联交易的事前认可
Capital/Financing Update Classification · 95% confidence The document is a statement from independent directors regarding the pre-approval of a non-public stock issuance involving related party transactions. It discusses the fairness and compliance of the transaction with regulatory requirements. The content focuses on approval and governance related to a capital raising event, specifically a non-public stock issuance. It is not a full report, financial statement, or earnings release, but rather an update or announcement related to financing activities and capital structure changes. Therefore, the document fits best under Capital/Financing Update (CAP). The document length is short and contains substantive content about the transaction, so it is not a mere announcement or certification.
2016-02-28 Chinese
第三届监事会第三次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of resolutions passed at the third meeting of the third Supervisory Board of Guangdong Taicheng Pharmaceutical Co., Ltd. It details decisions related to the termination of a 2015 non-public stock issuance, plans for a 2016 non-public issuance of A shares, including specifics on pricing, issuance quantity, lock-up periods, and use of proceeds. The document includes voting results and states that these proposals require further approval by the shareholders' meeting. The content focuses on the company's capital raising activities through non-public stock issuance and related corporate governance procedures. It is not a full financial report, earnings release, or management discussion, but rather an update on capital/financing activities and related board resolutions. The document length is under 5,000 characters but contains detailed substantive information about the financing plan and resolutions, not merely an announcement of a report publication. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-02-28 Chinese
关于召开2016年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2016 first extraordinary general meeting (临时股东大会) of Guangdong Taicheng Pharmaceutical Co., Ltd. It includes information about the meeting time, location, agenda items, voting procedures (including online voting), registration methods, and other logistical details. It also contains attachments such as proxy authorization forms and attendance receipts. The content is focused on informing shareholders about the meeting and how to participate and vote on specific proposals, including non-public stock issuance and related matters. There are no financial statements, audit opinions, earnings data, or management discussions present. The document is not a report itself but a formal notification and procedural guide for a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than solicitation materials or voting results, it aligns best with Proxy Solicitation & Information Statement (PSI).
2016-02-28 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.